{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T13:43:22Z","timestamp":1768311802482,"version":"3.49.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The scientific and technological research and application of thoracoscopy in lung disease surgery","award":["2017BA046"],"award-info":[{"award-number":["2017BA046"]}]},{"name":"The Application and promotion of thoracoscopy in chest diseases","award":["CGZH201703"],"award-info":[{"award-number":["CGZH201703"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Bioinformatics"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Esophageal adenocarcinoma (EAC) is an aggressive malignancy with a poor prognosis. The immune-related genes (IRGs) are crucial to immunocytes tumor infiltration. This study aimed to construct a IRG-related prediction signature in EAC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The related data of EAC patients and IRGs were obtained from the TCGA and ImmPort database, respectively. The cox regression analysis constructed the prediction signature and explored the transcription factors regulatory network through the Cistrome database. TIMER database and CIBERSORT analytical tool were utilized to explore the immunocytes infiltration analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The prediction signature with 12 IRGs (ADRM1, CXCL1, SEMG1, CCL26, CCL24, AREG, IL23A, UCN2, FGFR4, IL17RB, TNFRSF11A, and TNFRSF21) was constructed. Overall survival (OS) curves indicate that the survival rate of the high-risk group is significantly shorter than the low-risk group (<jats:italic>P<\/jats:italic>\u2009=\u20097.26e\u221207), and the AUC of 1-, 3- and 5- year survival prediction rates is 0.871, 0.924, and 0.961, respectively. Compared with traditional features, the ROC curve of the risk score in the EAC patients (0.967) is significant than T (0.57), N (0.738), M (0.568), and Stage (0.768). Moreover, multivariate Cox analysis and Nomogram of risk score are indicated that the 1-year and 3-year survival rates of patients are accurate by the combined analysis of the risk score, Sex, M stage, and Stage (The AUC of 1- and 3-years are 0.911, and 0.853).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The 12 prognosis-related IRGs might be promising therapeutic targets for EAC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12859-021-04456-2","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T08:02:57Z","timestamp":1635753777000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Development of a prognostic signature of patients with esophagus adenocarcinoma by using immune-related genes"],"prefix":"10.1186","volume":"22","author":[{"given":"Xiangxin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutao","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,1]]},"reference":[{"issue":"6","key":"4456_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"4456_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.20138","volume":"62","author":"R Siegel","year":"2012","unstructured":"Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10\u201329.","journal-title":"CA Cancer J Clin"},{"key":"4456_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3389\/fonc.2020.00175","volume":"10","author":"NE Annels","year":"2020","unstructured":"Annels NE, Simpson GR, Pandha H. Modifying the non-muscle invasive bladder cancer immune microenvironment for optimal therapeutic response. Front Oncol. 2020;10:175.","journal-title":"Front Oncol"},{"issue":"16","key":"4456_CR4","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1182\/blood-2010-02-269894","volume":"116","author":"W Ding","year":"2010","unstructured":"Ding W, Knox TR, Tschumper RC, Wu W, Schwager SM, Boysen JC, Jelinek DF, Kay NE. Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch. Blood. 2010;116(16):2984\u201393.","journal-title":"Blood"},{"key":"4456_CR5","first-page":"1","volume":"344","author":"WH Fridman","year":"2011","unstructured":"Fridman WH, Galon J, Dieu-Nosjean MC, Cremer I, Fisson S, Damotte D, Pag\u00e8s F, Tartour E, Saut\u00e8s-Fridman C. Immune infiltration in human cancer: prognostic significance and disease control. Curr Top Microbiol Immunol. 2011;344:1\u201324.","journal-title":"Curr Top Microbiol Immunol"},{"key":"4456_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbi.2015.07.019","volume":"53","author":"P Domingues","year":"2016","unstructured":"Domingues P, Gonz\u00e1lez-Tablas M, Otero \u00c1, Pascual D, Miranda D, Ruiz L, Sousa P, Ciudad J, Gon\u00e7alves JM, Lopes MC, et al. Tumor infiltrating immune cells in gliomas and meningiomas. Brain Behav Immun. 2016;53:1\u201315.","journal-title":"Brain Behav Immun"},{"issue":"2","key":"4456_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crin\u00f2 L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123\u201335.","journal-title":"N Engl J Med"},{"issue":"18","key":"4456_CR8","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2014.58.1041","volume":"33","author":"DF McDermott","year":"2015","unstructured":"McDermott DF, Drake CG, Sznol M, Choueiri TK, Powderly JD, Smith DC, Brahmer JR, Carvajal RD, Hammers HJ, Puzanov I, et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol. 2015;33(18):2013\u201320.","journal-title":"J Clin Oncol"},{"key":"4456_CR9","doi-asserted-by":"crossref","unstructured":"Pagni F, Guerini-Rocco E, Schultheis AM, Grazia G, Rijavec E, Ghidini M, Lopez G, Venetis K, Croci GA, Malapelle U et al. Targeting immune-related biological processes in solid tumors: we do need biomarkers. Int J Mol Sci. 2019; 20(21).","DOI":"10.3390\/ijms20215452"},{"issue":"26","key":"4456_CR10","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521\u201332.","journal-title":"N Engl J Med"},{"issue":"10066","key":"4456_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255\u201365.","journal-title":"Lancet"},{"issue":"20","key":"4456_CR12","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919\u201329.","journal-title":"N Engl J Med"},{"issue":"10111","key":"4456_CR13","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461\u201371.","journal-title":"Lancet"},{"issue":"11","key":"4456_CR14","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1001\/jamaoncol.2017.1609","volume":"3","author":"B Li","year":"2017","unstructured":"Li B, Cui Y, Diehn M, Li R. Development and validation of an individualized immune prognostic signature in early-stage nonsquamous non-small cell lung cancer. JAMA Oncol. 2017;3(11):1529\u201337.","journal-title":"JAMA Oncol"},{"issue":"1","key":"4456_CR15","doi-asserted-by":"publisher","first-page":"9912","DOI":"10.1038\/s41598-018-28299-9","volume":"8","author":"J Han","year":"2018","unstructured":"Han J, Chen M, Wang Y, Gong B, Zhuang T, Liang L, Qiao H. Identification of biomarkers based on differentially expressed genes in papillary thyroid carcinoma. Sci Rep. 2018;8(1):9912.","journal-title":"Sci Rep"},{"issue":"2","key":"4456_CR16","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3892\/ol.2020.12377","volume":"21","author":"JJ Wang","year":"2021","unstructured":"Wang JJ, Wang H, Zhu BL, Wang X, Qian YH, Xie L, Wang WJ, Zhu J, Chen XY, Wang JM, et al. Development of a prognostic model of glioma based on immune-related genes. Oncol Lett. 2021;21(2):116.","journal-title":"Oncol Lett"},{"key":"4456_CR17","doi-asserted-by":"crossref","unstructured":"Huo J, Wu L, Zang Y: A Prognostic model of 15 immune-related gene pairs associated with tumor mutation burden for hepatocellular carcinoma. Front Mol Biosci. 2020; 7:581354.","DOI":"10.3389\/fmolb.2020.581354"},{"key":"4456_CR18","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3389\/fgene.2020.00989","volume":"11","author":"X Guo","year":"2020","unstructured":"Guo X, Wang Y, Zhang H, Qin C, Cheng A, Liu J, Dai X, Wang Z. Identification of the prognostic value of immune-related genes in esophageal cancer. Front Genet. 2020;11:989.","journal-title":"Front Genet"},{"key":"4456_CR19","doi-asserted-by":"crossref","unstructured":"Lan T, Liu W, Lu Y, Luo H. A five-gene signature for predicting overall survival of esophagus adenocarcinoma. Medicine (Baltimore) 2021; 100(14):e25305.","DOI":"10.1097\/MD.0000000000025305"},{"key":"4456_CR20","doi-asserted-by":"crossref","unstructured":"Wang L, Wei Q, Zhang M, Chen L, Li Z, Zhou C, He M, Wei M, Zhao L. Identification of the prognostic value of immune gene signature and infiltrating immune cells for esophageal cancer patients. Int Immunopharmacol 2020; 87:106795.","DOI":"10.1016\/j.intimp.2020.106795"},{"key":"4456_CR21","doi-asserted-by":"crossref","unstructured":"Bhattacharya S, Dunn P, Thomas CG, Smith B, Schaefer H, Chen J, Hu Z, Zalocusky KA, Shankar RD, Shen-Orr SS et al. ImmPort, toward repurposing of open access immunological assay data for translational and clinical research. Sci Data 2018; 5:180015.","DOI":"10.1038\/sdata.2018.15"},{"issue":"21","key":"4456_CR22","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1158\/0008-5472.CAN-17-0327","volume":"77","author":"S Mei","year":"2017","unstructured":"Mei S, Meyer CA, Zheng R, Qin Q, Wu Q, Jiang P, Li B, Shi X, Wang B, Fan J, et al. Cistrome cancer: a web resource for integrative gene regulation modeling in cancer. Cancer Res. 2017;77(21):e19\u201322.","journal-title":"Cancer Res"},{"issue":"4","key":"4456_CR23","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1093\/carcin\/bgw018","volume":"37","author":"L Krause","year":"2016","unstructured":"Krause L, Nones K, Loffler KA, Nancarrow D, Oey H, Tang YH, Wayte NJ, Patch AM, Patel K, Brosda S, et al. Identification of the CIMP-like subtype and aberrant methylation of members of the chromosomal segregation and spindle assembly pathways in esophageal adenocarcinoma. Carcinogenesis. 2016;37(4):356\u201365.","journal-title":"Carcinogenesis"},{"issue":"9","key":"4456_CR24","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1101\/gr.132159.111","volume":"22","author":"T Derrien","year":"2012","unstructured":"Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, Guernec G, Martin D, Merkel A, Knowles DG, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. 2012;22(9):1775\u201389.","journal-title":"Genome Res"},{"key":"4456_CR25","doi-asserted-by":"crossref","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015, 43(7):e47.","DOI":"10.1093\/nar\/gkv007"},{"issue":"5","key":"4456_CR26","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284\u20137.","journal-title":"OMICS"},{"issue":"7","key":"4456_CR27","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, Khodadoust MS, Esfahani MS, Luca BA, Steiner D, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37(7):773\u201382.","journal-title":"Nat Biotechnol"},{"issue":"21","key":"4456_CR28","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","volume":"77","author":"T Li","year":"2017","unstructured":"Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B, Liu XS. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108\u201310.","journal-title":"Cancer Res"},{"issue":"2","key":"4456_CR29","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.coi.2013.03.004","volume":"25","author":"H Angell","year":"2013","unstructured":"Angell H, Galon J. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol. 2013;25(2):261\u20137.","journal-title":"Curr Opin Immunol"},{"issue":"8","key":"4456_CR30","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.3909","volume":"21","author":"AJ Gentles","year":"2015","unstructured":"Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, Nair VS, Xu Y, Khuong A, Hoang CD, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938\u201345.","journal-title":"Nat Med"},{"issue":"11","key":"4456_CR31","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1134\/S0006297916110043","volume":"81","author":"AV Bogolyubova","year":"2016","unstructured":"Bogolyubova AV, Belousov PV. Inflammatory immune infiltration in human tumors: role in pathogenesis and prognostic and diagnostic value. Biochemistry (Mosc). 2016;81(11):1261\u201373.","journal-title":"Biochemistry (Mosc)"},{"issue":"6","key":"4456_CR32","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/CCO.0000000000000234","volume":"27","author":"D Bedognetti","year":"2015","unstructured":"Bedognetti D, Hendrickx W, Marincola FM, Miller LD. Prognostic and predictive immune gene signatures in breast cancer. Curr Opin Oncol. 2015;27(6):433\u201344.","journal-title":"Curr Opin Oncol"},{"issue":"2","key":"4456_CR33","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.3390\/ijms14023094","volume":"14","author":"MS Fejzo","year":"2013","unstructured":"Fejzo MS, Anderson L, von Euw EM, Kalous O, Avliyakulov NK, Haykinson MJ, Konecny GE, Finn RS, Slamon DJ. Amplification target ADRM1: role as an oncogene and therapeutic target for ovarian cancer. Int J Mol Sci. 2013;14(2):3094\u2013109.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"4456_CR34","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s10585-014-9663-4","volume":"31","author":"SH Jang","year":"2014","unstructured":"Jang SH, Park JW, Kim HR, Seong JK, Kim HK. ADRM1 gene amplification is a candidate driver for metastatic gastric cancers. Clin Exp Metastasis. 2014;31(6):727\u201333.","journal-title":"Clin Exp Metastasis"},{"issue":"6","key":"4456_CR35","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.ccr.2013.11.001","volume":"24","author":"RK Anchoori","year":"2013","unstructured":"Anchoori RK, Karanam B, Peng S, Wang JW, Jiang R, Tanno T, Orlowski RZ, Matsui W, Zhao M, Rudek MA, et al. A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13\/ADRM1 as a therapy for cancer. Cancer Cell. 2013;24(6):791\u2013805.","journal-title":"Cancer Cell"},{"issue":"3","key":"4456_CR36","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1159\/000490210","volume":"47","author":"GY Yu","year":"2018","unstructured":"Yu GY, Wang X, Zheng SS, Gao XM, Jia QA, Zhu WW, Lu L, Jia HL, Chen JH, Dong QZ, et al. RA190, a proteasome subunit ADRM1 inhibitor, suppresses intrahepatic cholangiocarcinoma by inducing NF-KB-mediated cell apoptosis. Cell Physiol Biochem. 2018;47(3):1152\u201366.","journal-title":"Cell Physiol Biochem"},{"issue":"8","key":"4456_CR37","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/1440-1681.13103","volume":"46","author":"X Yu","year":"2019","unstructured":"Yu X, Yan N, Li Z, Hua Y, Chen W. FGF19 sustains the high proliferative ability of keratinocytes in psoriasis through the regulation of Wnt\/GSK-3\u03b2\/\u03b2-catenin signalling via FGFR4. Clin Exp Pharmacol Physiol. 2019;46(8):761\u20139.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"29","key":"4456_CR38","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.1038\/sj.onc.1203650","volume":"19","author":"KC Hart","year":"2000","unstructured":"Hart KC, Robertson SC, Kanemitsu MY, Meyer AN, Tynan JA, Donoghue DJ. Transformation and stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene. 2000;19(29):3309\u201320.","journal-title":"Oncogene"},{"issue":"12","key":"4456_CR39","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1038\/s41418-019-0321-x","volume":"26","author":"SP Turunen","year":"2019","unstructured":"Turunen SP, von Nandelstadh P, \u00d6hman T, Gucciardo E, Seashore-Ludlow B, Martins B, Rantanen V, Li H, H\u00f6pfner K, \u00d6stling P, et al. FGFR4 phosphorylates MST1 to confer breast cancer cells resistance to MST1\/2-dependent apoptosis. Cell Death Differ. 2019;26(12):2577\u201393.","journal-title":"Cell Death Differ"},{"issue":"6","key":"4456_CR40","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1021\/acs.jmedchem.8b01531","volume":"62","author":"X Lu","year":"2019","unstructured":"Lu X, Chen H, Patterson AV, Smaill JB, Ding K. Fibroblast growth factor receptor 4 (FGFR4) selective inhibitors as hepatocellular carcinoma therapy: advances and prospects. J Med Chem. 2019;62(6):2905\u201315.","journal-title":"J Med Chem"},{"issue":"11","key":"4456_CR41","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1038\/s12276-020-00524-4","volume":"52","author":"H Huynh","year":"2020","unstructured":"Huynh H, Prawira A, Le TBU, Vu TC, Hao HX, Huang A, Wang Y, Porta DG. FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma. Exp Mol Med. 2020;52(11):1857\u201368.","journal-title":"Exp Mol Med"},{"issue":"12","key":"4456_CR42","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1158\/2159-8290.CD-19-1156","volume":"9","author":"V Subbiah","year":"2019","unstructured":"Subbiah V, Pal SK. Precision oncology for hepatocellular cancer: slivering the liver by FGF19-FGF4-KLB pathway inhibition. Cancer Discov. 2019;9(12):1646\u20139.","journal-title":"Cancer Discov"},{"issue":"24","key":"4456_CR43","doi-asserted-by":"publisher","first-page":"6999","DOI":"10.1158\/0008-5472.CAN-17-1865","volume":"77","author":"JJ Joshi","year":"2017","unstructured":"Joshi JJ, Coffey H, Corcoran E, Tsai J, Huang CL, Ichikawa K, Prajapati S, Hao MH, Bailey S, Wu J, et al. H3B\u20136527 is a potent and selective inhibitor of FGFR4 in FGF19-driven hepatocellular carcinoma. Cancer Res. 2017;77(24):6999\u20137013.","journal-title":"Cancer Res"},{"issue":"1","key":"4456_CR44","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1038\/s41467-021-23042-x","volume":"12","author":"S Roy","year":"2021","unstructured":"Roy S, Rizvi ZA, Clarke AJ, Macdonald F, Pandey A, Zaiss DMW, Simon AK, Awasthi A. EGFR-HIF1\u03b1 signaling positively regulates the differentiation of IL-9 producing T helper cells. Nat Commun. 2021;12(1):3182.","journal-title":"Nat Commun"},{"issue":"4","key":"4456_CR45","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1097\/01.sla.0000118751.95179.c6","volume":"239","author":"MM Abdel-Latif","year":"2004","unstructured":"Abdel-Latif MM, O\u2019Riordan J, Windle HJ, Carton E, Ravi N, Kelleher D, Reynolds JV. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett\u2019s metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg. 2004;239(4):491\u2013500.","journal-title":"Ann Surg"},{"issue":"23","key":"4456_CR46","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1038\/onc.2013.268","volume":"33","author":"CK Huang","year":"2014","unstructured":"Huang CK, Yang CY, Jeng YM, Chen CL, Wu HH, Chang YC, Ma C, Kuo WH, Chang KJ, Shew JY, et al. Autocrine\/paracrine mechanism of interleukin-17B receptor promotes breast tumorigenesis through NF-\u03baB-mediated antiapoptotic pathway. Oncogene. 2014;33(23):2968\u201377.","journal-title":"Oncogene"},{"issue":"69","key":"4456_CR47","doi-asserted-by":"publisher","first-page":"113360","DOI":"10.18632\/oncotarget.23008","volume":"8","author":"E Laprevotte","year":"2017","unstructured":"Laprevotte E, Cochaud S, du Manoir S, Lapierre M, Dejou C, Philippe M, Giustiniani J, Frewer KA, Sanders AJ, Jiang WG, et al. The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1\/2 pathway. Oncotarget. 2017;8(69):113360\u201372.","journal-title":"Oncotarget"},{"issue":"3","key":"4456_CR48","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1084\/jem.20141702","volume":"212","author":"HH Wu","year":"2015","unstructured":"Wu HH, Hwang-Verslues WW, Lee WH, Huang CK, Wei PC, Chen CL, Shew JY, Lee EY, Jeng YM, Tien YW, et al. Targeting IL-17B-IL-17RB signaling with an anti-IL-17RB antibody blocks pancreatic cancer metastasis by silencing multiple chemokines. J Exp Med. 2015;212(3):333\u201349.","journal-title":"J Exp Med"},{"key":"4456_CR49","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.canlet.2016.01.043","volume":"387","author":"T Wu","year":"2017","unstructured":"Wu T, Dai Y. Tumor microenvironment and therapeutic response. Cancer Lett. 2017;387:61\u20138.","journal-title":"Cancer Lett"},{"issue":"1","key":"4456_CR50","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s40425-017-0283-9","volume":"5","author":"LME Janssen","year":"2017","unstructured":"Janssen LME, Ramsay EE, Logsdon CD, Overwijk WW. The immune system in cancer metastasis: friend or foe? J Immunother Cancer. 2017;5(1):79.","journal-title":"J Immunother Cancer"}],"container-title":["BMC Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-021-04456-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12859-021-04456-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-021-04456-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T09:03:15Z","timestamp":1635757395000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbioinformatics.biomedcentral.com\/articles\/10.1186\/s12859-021-04456-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["4456"],"URL":"https:\/\/doi.org\/10.1186\/s12859-021-04456-2","relation":{},"ISSN":["1471-2105"],"issn-type":[{"value":"1471-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,1]]},"assertion":[{"value":"9 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"536"}}